At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 207 enrolled
Drug / intervention
fibrinogen infusiondrug
Likely dose
fibrinogen infusion 2 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis: a Pilot Probe Randomized Controlled Trial (FibER)
In Brief
A Phase 3 clinical trial evaluating fibrinogen infusion for Intracranial Hemorrhages and Ischemic Stroke. Completed, enrolled 207 participants across 1 site.
Detailed Summary
Fibrinogen replacement could prevent haemorrhagic complications in ischemic stroke patients with secondary post-rtPA hypofibrinogenemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracranial Hemorrhages, Ischemic Stroke
CountriesItaly
CollaboratorsMinistero della Salute, Italy
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartFeb 2022
First PostedMar 2022
Primary CompletionDec 2024
Study CompletionMay 2025
TodayJul 2026
First PostedMar 29, 2022
Enrollment StartFeb 8, 2022
Primary CompletionDec 31, 2024
Study CompletionMay 27, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.3 years ago
Interventions
fibrinogen infusiondrug
fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia